1. Home
  2. BRT vs CABA Comparison

BRT vs CABA Comparison

Compare BRT & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BRT Apartments Corp. (MD)

BRT

BRT Apartments Corp. (MD)

HOLD

Current Price

$14.23

Market Cap

269.9M

Sector

Real Estate

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.93

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRT
CABA
Founded
1972
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
269.9M
319.6M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
BRT
CABA
Price
$14.23
$2.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$19.75
$14.50
AVG Volume (30 Days)
65.4K
1.9M
Earning Date
05-08-2026
05-14-2026
Dividend Yield
7.04%
N/A
EPS Growth
N/A
10.26
EPS
N/A
N/A
Revenue
$97,028,000.00
N/A
Revenue This Year
$3.82
N/A
Revenue Next Year
$5.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.46
N/A
52 Week Low
$13.18
$1.11
52 Week High
$16.69
$3.78

Technical Indicators

Market Signals
Indicator
BRT
CABA
Relative Strength Index (RSI) 53.12 44.25
Support Level $13.18 $2.32
Resistance Level $15.02 $3.34
Average True Range (ATR) 0.29 0.20
MACD 0.04 -0.02
Stochastic Oscillator 57.26 5.89

Price Performance

Historical Comparison
BRT
CABA

About BRT BRT Apartments Corp. (MD)

BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: